Photo of Karen M. Winkfield,  MD, PhD

Karen M. Winkfield, MD, PhD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-1159
Fax: (617) 726-3603


kwinkfield@partners.org

Karen M. Winkfield, MD, PhD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Radiation Oncology, Harvard Medical School
  • Assistant in Radiation Oncology, Radiation Oncology, Massachusetts General Hospital
  • Director, Hematologic Services, Radiation Oncology, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Black American's have the highest cancer mortality of all racial/ethnic groups for almost all disease sites. Although tumor biology for some cancers, including breast and prostate cancer, appear to be more aggressive, presentation at more advanced stages of disease contributes to lower survival rates. While progress is being made and cancer screening rates have increased among blacks, there is confusion regarding recent screening recommendations for breast and prostate cancer. With increased cancer mortality, patients must be well-advised about their cancer risks and if diagnosed, must be adequately informed about treatment options. Physician bias may play a role in the difference seen in disease management and outcomes, yet patient beliefs about cancer and its treatment, including the belief that cancer is inevitable and cannot be treated or negative perceptions regarding treatment modalities, may be contributing factors as well. My research aims to identify and address myths and beliefs that influence decisions related to cancer screening and treatment among black Americans, and to develop an interactive educational tool to provide accurate information regarding health, cancer screening, and cancer treatments, including enrollment in clinical trials, in a culturally sensitive manner.

Publications

Powered by Harvard Catalyst
  • Hoppe BS, Hodgson DC, Advani R, Dabaja BS, Flowers CR, Ha CS, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Terezakis SA, Winkfield KM, Younes A, Constine LS. ACR Appropriateness Criteria: Localized nodal indolent lymphoma. Oncology (Huntingt) 2013; 27:786-94. PubMed
  • Winkfield KM, Gabeau D. Why workforce diversity in oncology matters. Int J Radiat Oncol Biol Phys 2013; 85:900-1. PubMed
  • Nardi V, Winkfield KM, Ok CY, Niemierko A, Kluk MJ, Attar EC, Garcia-Manero G, Wang SA, Hasserjian RP. Acute Myeloid Leukemia and Myelodysplastic Syndromes After Radiation Therapy Are Similar to De Novo Disease and Differ From Other Therapy-Related Myeloid Neoplasms. J Clin Oncol 2012. PubMed
  • Winkfield KM, Chen MH, Dosoretz DE, Salenius SA, Katin M, Ross R, D'Amico AV. Race and Survival Following Brachytherapy-based Treatment for Men With Localized or Locally Advanced Adenocarcinoma of the Prostate. Int J Radiat Oncol Biol Phys 2011. PubMed
  • Winkfield KM, Tsai HK, Yao X, Larson E, Neuberg D, Pomeroy SL, Ullrich NJ, Cohen LE, Kieran MW, Scott RM, Goumnerova LC, Marcus KJ. Long-term clinical outcomes following treatment of childhood craniopharyngioma. Pediatr Blood Cancer 2010. PubMed
  • Winkfield KM, Harris JR. Effective local therapy and long-term survival in breast cancer. Oncology (Huntingt) 2009; 23:669-75. PubMed
  • Winkfield KM and Albert MA. Unanswered questions regarding the effect of androgen deprivation therapy for prostate cancer on cardiovascular disease risk in black men Curr Cardio Risk Rep 2010; 4:311-17.